University Hospital of Zurich
Zurich, Canton of Zurich, 8091, Switzerland
NCT Number: NCT05869422
The goal of this study is to investigate the efficacy of a low dose iron supplement (6mg) compared to a placebo tablet.
Looking for future studies?
Notify Me18 year–50 year
Female
Interventional
Not applicable
Zurich, Canton of Zurich, 8091, Switzerland
The established therapy for iron-deficiency today is oral iron supplementation. However, this often leads to side effects such as constipation, black stools, nausea, and abdominal pain. There are some studies that have compared the efficacy of low-dose iron with normal-dose iron. These showed that the side effects are dose-dependent. Furthermore, some studies have shown that the uptake capacity of high-dose iron is less efficient due to the upregulation of hepcidin. In a pilot study with low-dose iron (6mg per tablet), a significant increase in iron was shown, which can be explained by a lower hepcidin release. Therefore, the investigators would like to show the efficacy of the low-dose iron product in a placebo-controlled setting. Furthermore, the goal is to examine the reduction of side effects before and after administration of the iron and placebo tablet. Additionally, a potential increase of low blood pressure to normal blood pressure will be investigated. There will be two groups of women: one group will be given a low-dose iron supplement of two tablets containing each 6mg for 2 months (60 days), the other one will get two placebo tablet for 2 months, accordingly.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
60 ± 5 days of daily oral iron supplementation.
60 ± 5 days of daily oral placebo intake.
Time frame: 60 ± 5 days
significant change of serum-ferritin under supplementation
Time frame: 60 ± 5 days
change of blood pressure (systolic and diastolic blood pressure)
Time frame: 60 ± 5 days
change of blood sugar levels
Time frame: 60 ± 5 days
change of lipid status (total cholesterol, HDL, LDL, triglycerides)
Time frame: 60 ± 5 days
Incidence of adverse events during 2 months under low dose iron supplementation and placebo treatment.
Dr. Krayenbühl GmbH
Industry
Randomised, Double-blind, Placebo-controlled Clinical Trial Evaluating the Effectiveness of a Low-dose Iron Supplementation in Non-anaemic Iron-deficient Women
Acronym: PCLDIT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04228627
Anemia, Hematologic Diseases
Lahore, Punjab Province, Pakistan
View Trial DetailsNCT06657677
Iron Deficiencies, Iron Deficiency (Without Anemia)
Zurich, Canton of Zurich, Switzerland
View Trial DetailsNCT05467423
Iron Deficiencies, Iron Deficiency (Without Anemia)
Zurich, Switzerland
View Trial DetailsNCT06021171
Anemia, Anemia, Hypochromic
Wilkes-Barre, Pennsylvania, United States
View Trial Details